Live News Categoriesequity

Shanghai Shen Lian Biomedical Corporation (688098.SS) News

Track canonical SquawkNews coverage tagged to 688098.SS, Shanghai Shen Lian Biomedical Corporation. This hub brings together deduplicated headlines about shanghai stock exchange, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol 688098.SS Asset equity Sector Markets 90 days 1 Last 8.34 Updated Sep 20, 2026, 07:57 AM UTC Open live news feed

L BRIEF — Shanghai Shen Lian Says Phase II Clinical Trial Of UB — 221 Meets Primary Endpoint Sept 20 (Reuters) — Shanghai Shen Lian Biomedical Corp: Says Phase Ii Clinical Trial Of Ub-221 For Chronic Spontaneous Urticaria Treatment Meets Primary Endpoint Source text Further company coverage: (Reporting by Hong K NEWS | Sep 20, 2026, 07:57 AM UTC